Intake estimation of total and individual flavan-3-ols, proanthocyanidins and theaflavins, their food sources and determinants in the European Prospective Investigation into Cancer and Nutrition (EPIC) study by Knaze, Viktoria et al.
Intake estimation of total and individual flavan-3-ols, proanthocyanidins and
theaflavins, their food sources and determinants in the European Prospective
Investigation into Cancer and Nutrition (EPIC) study
Viktoria Knaze1, Raul Zamora-Ros1*, Leila Luja´n-Barroso1, Isabelle Romieu2, Augustin Scalbert2,
Nadia Slimani2, Elio Riboli3, Caroline T. M. van Rossum4, H. Bas Bueno-de-Mesquita4,5,
Antonia Trichopoulou6,7, Vardis Dilis6,7, Konstantinos Tsiotas6, Guri Skeie8, Dagrun Engeset8,
J. Ramo´n Quiro´s9, Esther Molina10,11, Jose´ Marı´a Huerta11,12, Francesca Crowe13, Elisabet Wirfa¨l14,
Ulrika Ericson14, Petra H. M. Peeters3,15, Rudolf Kaaks16, Birgit Teucher16, Gerd Johansson17,
Ingegerd Johansson18, Rosario Tumino19, Heiner Boeing20, Dagmar Drogan20, Pilar Amiano11,21,
Amalia Mattiello22, Kay-Tee Khaw23, Robert Luben23, Vittorio Krogh24, Eva Ardana´z11,25,
Carlotta Sacerdote26, Simonetta Salvini27, Kim Overvad28, Anne Tjønneland29, Anja Olsen29,
Marie-Christine Boutron-Ruault30,31, Guy Fagherazzi30,31, Florence Perquier30,31 and Carlos A. Gonza´lez1
1Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology
(ICO-IDIBELL), Avda Gran Via 199-203 08907 L’Hospitalet de Llobregat, Barcelona, Spain
2Dietary Exposure Assessment Group, International Agency for Research on Cancer (IARC), Lyon, France
3Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London,
London, UK
4National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands
5Department of Gastroenterology and Hepatology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands
6WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics,
University of Athens Medical School, Athens, Greece
7Hellenic Health Foundation, Athens, Greece
8Department of Community Medicine, University of Tromsø, Tromsø, Norway
9Public Health and Health Planning Directorate, Asturias, Spain
10Andalusian School of Public Health, Granada, Spain
11CIBER Epidemiologı´a y Salud Pu´blica (CIBERESP), Barcelona, Spain
12Department of Epidemiology, Murcia Regional Health Authority, Murcia, Spain
13Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
14Department of Clinical Sciences in Malmo¨, Nutrition Epidemiology, Lund University, Malmo¨, Sweden
15Julius Center, University Medical Center Utrecht, Utrecht, The Netherlands
16Department of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
17Department of Clinical Medicine and Public Health/Nutritional Research, Umea˚ University, Umea˚, Sweden
18Department of Odontology/Cariology, Umea˚ University, Umea˚, Sweden
19Cancer Registry and Histopathology Unit, “Civile M.P. Arezzo” Hospital, Ragusa, Italy
20Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbru¨cke, Nuthetal, Germany
21Public Health Division of Gipuzkoa, Institute Investigation BioDonostia, Basque Government, San Sebastian, Spain
22Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
23School of Clinical Medicine, University of Cambridge, Cambridge, UK
24Nutritional Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
25Navarre Public Health Institute, Pamplona, Spain
26Center for Cancer Prevention (CPO-Piemonte), and Human Genetic Foundation (HuGeF), Torino, Italy
27Molecular and Nutritional Epidemiology Unit, ISPO Cancer Prevention and Research Institute, Florence, Italy
Abbreviations: 24-HDR, 24 h dietary recall; EPIC, European Prospective Investigation into Cancer and Nutrition; FCDB, food composition database;
MED, Mediterranean; PA, proanthocyanidins; USDA, US Department of Agriculture.
*Corresponding author: R. Zamora-Ros, fax þ34 932607787, email rzamora@iconcologia.net
British Journal of Nutrition (2012), 108, 1095–1108 doi:10.1017/S0007114511006386

















28Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark
29Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
30INSERM, Centre for Research in Epidemiology and Population Health, U1018, Institut Gustave Roussy, F-94805
Villejuif, France
31Paris South University, UMRS 1018, F-94805 Villejuif, France
(Submitted 27 July 2011 – Final revision received 13 October 2011 – Accepted 22 October 2011 – First published online 20 December 2011)
Abstract
Epidemiological studies suggest health-protective effects of flavan-3-ols and their derived compounds on chronic diseases. The present
study aimed to estimate dietary flavan-3-ol, proanthocyanidin (PA) and theaflavin intakes, their food sources and potential determinants
in the European Prospective Investigation into Cancer and Nutrition (EPIC) calibration cohort. Dietary data were collected using a standar-
dised 24 h dietary recall software administered to 36 037 subjects aged 35–74 years. Dietary data were linked with a flavanoid food
composition database compiled from the latest US Department of Agriculture and Phenol-Explorer databases and expanded to include
recipes, estimations and retention factors. Total flavan-3-ol intake was the highest in UK Health-conscious men (453·6 mg/d) and
women of UK General population (377·6 mg/d), while the intake was the lowest in Greece (men: 160·5 mg/d; women: 124·8 mg/d).
Monomer intake was the highest in UK General population (men: 213·5 mg/d; women: 178·6 mg/d) and the lowest in Greece
(men: 26·6 mg/d in men; women: 20·7 mg/d). Theaflavin intake was the highest in UK General population (men: 29·3 mg/d; women:
25·3 mg/d) and close to zero in Greece and Spain. PA intake was the highest in Asturias (men: 455·2 mg/d) and San Sebastian (women:
253 mg/d), while being the lowest in Greece (men: 134·6 mg/d; women: 101·0 mg/d). Except for the UK, non-citrus fruits (apples/
pears) were the highest contributors to the total flavan-3-ol intake. Tea was the main contributor of total flavan-3-ols in the UK.
Flavan-3-ol, PA and theaflavin intakes were significantly different among all assessed groups. This study showed heterogeneity in
flavan-3-ol, PA and theaflavin intake throughout the EPIC countries.
Key words: Flavan-3-ols: Proanthocyanidins: Theaflavins: Intake: European Prospective Investigation into Cancer and
Nutrition-Europe
Flavan-3-ols or flavanols, terms used interchangeably, are
compounds that belong to a polyphenol subclass called
flavonoids, which share a common C6–C3–C6 skeleton.
Flavan-3-ols are perhaps the most structurally complex in
the flavonoid subclass ranging from simple monomers (such
as catechin and its isomer epicatechin) to oligomers (from
dimers to decamers), polymers (.10mers) and other derived
compounds (e.g. theaflavins and thearubigins). The oligo
and polymers of flavan-3-ols are also referred to as condensed
tannins or proanthocyanidins (PA), named for their ability
to yield anthocyanidins when heated in acidic media(1).
Enzymatic and non-enzymatic oxidation of (gallo)catechins,
reactions characteristic of green tea fermentation, results in
flavanol-derived compounds: theaflavins and high-molecular-
weight thearubigins(1,2). Being much larger molecules, PA
and flavanol-derived compounds tend to be less bioavailable
and have different functional properties; therefore they are
often considered as separate groups of flavonoids(1,3).
Although their average degree of polymerisation can be esti-
mated, the structures of some high-molecular weight polymers
of PA and of most of the thearubigins have not been well
defined due to inadequate analytical methods(1).
Flavan-3-ol monomers are found ubiquitously in plants as
secondary metabolites(4). Flavan-3-ol monomers are most
abundant in fruits (e.g. berries, apples/pears, stone fruits),
barley, cocoa beans, nuts(5) and their derived products(6).
Gallocatechins are found, almost exclusively, in green tea
infusions(2,7) while flavanol-derived compounds, theaflavins
and thearubigins, are abundant in fermented black and
oolong teas(2). Common PA-rich foods are cocoa, berries,
nuts and some raw beans(5,8). Transformations and losses of
some flavonoid compounds during processing and cooking
are common and vary for different subclasses and even for
the individual compounds(9–11).
Total and individual compounds of flavan-3-ols have
been studied extensively in vitro for their antioxidant, anti-
inflammatory, immunomodulator and anti-carcinogenic
effects(12–14). A plethora of human intervention studies
currently available strongly suggests beneficial effects on
human health, particularly the effects of flavan-3-ol-rich
foods, such as tea, cocoa and chocolate(7,15,16). Intervention
studies involving various PA-rich sources such as red wine,
grape, pomegranate, chocolate and cranberry juice showed
numerous positive effects on antioxidant, CVD and endo-
thelial maintenance biomarkers(3). Given the limited reported
bioavailability of PA, particularly those having a high degree of
polymerisation (.3)(17), the observed action of PA-rich foods
in the body, with the exception of perhaps the intestinal
lumen, may be attributed to flavan-3-ol monomers, which
are systematically associated to PA and comprise 5–25 % in
these foods, or to other yet unidentified PA(3,18). Furthermore,
PA may also exert their action after their degradation by the
colonic microbiota and subsequent absorption(19). Indeed,
two Italian case–control studies suggested inverse associ-
ations between PA, but not flavan-3-ol monomer, intake and
gastric and colorectal cancers(20,21). Furthermore, the inverse
association augmented with increasing degrees of polymeris-
ation of PA in colorectal cancer cases(20) despite their observed

















decrease in absorption. Further research, particularly in pro-
spective studies, on individual flavan-3-ol and PA compounds
is clearly needed to clarify and confirm these potential effects.
Total intake of any nutrients is usually related to sex,
cultural, lifestyle and socio-economic factors that may affect
accessibility to and habitual consumption of health-promoting
foods. Studies in European Prospective Investigation into
Cancer and Nutrition (EPIC) Spain and the USA found signifi-
cant differences in total flavonoid intake between sexes
and among different age groups, socio-economic levels and
ethnic groups(22,23). Therefore, these factors need to be
taken into consideration when looking into associations of
these compounds and their dietary sources in disease preven-
tion. To our knowledge, there are few data on individual
flavan-3-ol intakes in the European population. The present
study aims to evaluate total, subclasses and individual dietary
intake of flavan-3-ols and their main food sources by EPIC
centre and geographical region, while taking into account
lifestyle, anthropometric and socio-demographic factors.
Materials and methods
Study population
EPIC is an ongoing prospective cohort study designed to
investigate the associations between diet, lifestyle and cancer
throughout ten Western European countries: Denmark,
France, Germany, Greece, Italy, Norway, Spain, Sweden,
The Netherlands and UK(24). The cohort includes approxi-
mately 366 000 women and 153 000 men, most of them aged
35–74 years, who were enrolled between 1992 and 2000 by
twenty-three centres. Some differences in methods of recruit-
ment exist between centres. Part of the Oxford (UK) cohort
was recruited from subjects who consumed a vegetarian-
type diet. This was designated a ‘Health-conscious’ group
and shall be distinguished from the UK General population
cohort which is a combined group of the UK Cambridge
and UK Oxford general population. The female part of the
cohort in Florence (Italy) and Utrecht (The Netherlands) is
composed of women who underwent breast cancer screening.
The French cohorts recruited women only, but from the mem-
bers of the health insurance scheme for the state-school
employees. The centres in Italy and Spain recruited mostly
blood donors. For the purpose of dietary consumption
patterns analysis, the initial twenty-three centres were later
redefined by geographical areas into twenty-seven centres(25).
The calibration subsample of the EPIC cohort study composed
of 36 994 subjects (8 % of the whole EPIC cohort), who were
recruited to be a random sample stratified by age, sex and
centre, and weighted for expected cancer cases in each
stratum of the main EPIC cohort study, was considered
herein. After exclusion of 945 subjects under 35 or over
74 years of age because of low participation in these age
categories, and sixteen subjects without baseline dietary
data, a total of 36 037 subjects were included. Approval for
the study was obtained from the ethical review boards of all
local recruiting research institutions. All participants provided
written informed consent.
Measurements of diet and other lifestyle factors
Dietary intake was measured with a standardised 24 h dietary
recall (24-HDR) administered via a computerised interview
programme (EPIC-SOFT) developed specifically for the EPIC
calibration study(25,26). The 24-HDR was administered in a
face-to-face interview, except in Norway where it was
obtained by telephone(27). A detailed description of the ration-
ale and methodology of the 24-HDR calibration study in the
EPIC cohort has been described elsewhere(24,28–30). Data on
socio-demographic and lifestyle factors, including educational
level, physical activity and smoking history were collected
at baseline through standardised questionnaires and clinical
examinations for the calibration sample(31–34). Age as well
as body weight and height were self-reported by the partici-
pants during the 24-HDR interview. The mean time interval
between these baseline questionnaire measures and the
24-HDR interview varied by country, from 1 d to 3 years(24).
Flavonoid Food Composition Database
The US Department of Agriculture (USDA) released a PA
database in 2004 and an updated flavonoid database in 2007,
with more analytical values for raw, cooked, canned and
commercially processed foods(35,36). In the process of combin-
ing the two USDA databases, we observed data duplicity of
the monomers. Since flavan-3-ols monomers (USDA database
on flavonoids)(35) and PA monomers (USDA database on
PA)(36) are the same molecules, the PA monomer data was
removed. We expanded these databases with analytical
values from the Phenol-Explorer database released in
2009(37). Approximately, 6·5 and 0·6 % of our database came
from USDA and Phenol-Explorer, respectively. Thus far,
these databases are the most complete and updated databases
on flavonoids/polyphenols and they evaluate and compile the
most worldwide food composition data published. We further
expanded our EPIC-specific food composition database
(FCDB) by estimating values for foods not present in either
of the two databases, but that had occurred in the 24-HDR.
Therefore, for our FCDB, we calculated estimated values
(92·9 %) including logical zeros (25·3 %), estimations based
on similar food items (22·5 %), application of retention factors
(27·7 %) and recipes (17·3 %). When there were no analytical
data provided for cooked foods by either USDA or Phenol-
Explorer, retention factors were applied. The retention factors
reported in various foods were between 42 and 74 % for cate-
chins and 0 and 95 % for tannins(38). Therefore, to simplify and
homogenise the calculations, we used the same retention
factors for all flavonoids, as in our previous studies(23,39,40).
They were 70, 35 and 25 % after frying, cooking in a micro-
wave oven and boiling, respectively(41). The final FCDB
created contained a total of 1877 food items. The unknown
composition values, without any analytical or estimated data,
were calculated as a zero by default and ranged from 2 %
(theaflavin gallates) to 16 % (epicatechin-3-gallates). Finally,
the 24-HDR food items were linked with the expanded
flavonoid FCDB using an ad hoc SQL (Structured Query
Language) application.


















General linear modelling was used for the calculation of
the adjusted daily mean (least squared) intake and standard
error using SPSS (version 17.0.0, SPSS, Inc.) for total flavan-
3-ols, their individual compounds and subgroups. The mean
intake was adjusted for age, weighted by season and day of
24-HDR and stratified by EPIC centre and age. Flavan-3-ol
monomers as aglycones included: catechin, epigallocatechin,
epicatechin, epicatechin-3-gallate, epigallocatechin-3-gallate,
gallocatechin and catechin-3-gallate. PA were divided into
the following subgroups: dimers, trimers, 4–6mers,
7–10mers and .10mers (polymers). Theaflavins included
compounds: theaflavin, theaflavin-3,30-digallate, theaflavin-30-
gallate and theaflavin-3-gallate. Although present in the USDA
database, due to the extensive limitations in analytical methods
currently employed to identify and quantify thearubigins,
we did not include them in our analysis of total flavan-3-
ols(1,41). Epigallocatechin, epicatechin-3-gallate, epigallocate-
chin-3-gallate, gallocatechin and catechin-3-gallate were later
combined into a single group called ‘(epi)gallocatechins’ due
to the resemblance among the chemical structures. Flavan-3-
ol monomer, PA and theaflavin intakes are calculated as the
sum of the individual compounds or subgroups and expressed
in mg/100 g of fresh weight. During the analysis of the related
factors and of the main food sources, EPIC centres were com-
bined by geographical regions into a Mediterranean (MED)
region (Greece, Italy, Spain and South of France) and
non-MED (non-MED) region (France other than the South
centre, Germany, The Netherlands, Norway, Denmark and
Sweden). The UK General population cohort and the
Health-conscious cohort presented similar intakes for flavan-
3-ols and their food sources but markedly different from all
others; therefore, in the socio-demographic analysis they
were kept as a separate UK region. The contribution of each
food and food group to the total and individual intake of
flavan-3-ols was calculated as a percentage. The general
linear modelling was also used in the comparison of the
mean intakes by socio-demographic, anthropometric and
lifestyle factors, adjusting for age, region, energy intake and
BMI, and weighted for season and day of 24-HDR. P values
,0·05 indicated significance.
Results
A south-to-north gradient in the daily mean intake of total and
monomers of flavan-3-ols and of theaflavins was observed
among EPIC centres in both men and women (Table 1). The
highest total flavan-3-ol intake was observed in the UK
Health-conscious men (453·6 mg/d) and in women of the
UK General population cohort (377·6 mg/d). The lowest total
intake was observed in Greek men (160·5 mg/d) and women
(124·8 mg/d). Flavan-3-ol monomer intake was the highest in
the UK General population (213·5 mg/d in men, 178·6 mg/d
in women) and the lowest in Greece (26·6 mg/d in men,
20·7 mg/d in women). Theaflavin intake was the highest in
the UK General population for both men (29·3 mg/d) and
women (25·3 mg/d). Daily theaflavin intake was close to
0 mg in Greece and in Spanish and southern Italian centres
(Ragusa, Naples and Florence). In contrast, daily intake of
total PA was the highest in Spanish centres (455·2 mg in men
from Asturias and 237·9 mg in women from San Sebastian),
followed by men in Turin (Italy) and women in Asturias
(Spain), respectively. However, PA intake was the lowest in
Greece (134·6 mg/d in men and 101·0 mg/d in women).
Intake amounts of the individual flavan-3-ols, theaflavins
and of PA subgroups are presented in Annexes 1 and 2. PA
subclass, particularly the group of polymers (.10mers), was
the highest contributor to the total flavan-3-ol intake
(Table 2). Flavan-3-ol monomers were the second highest
contributors to the total intake, providing contribution of
between 18·6 % in the MED region and 44·9 % in the UK.
Catechins and epicatechins, equally, were the main single-
compound contributors in the MED region, while in the
non-MED and UK regions it was the epigallocatechin-3-gallate
monomers. Theaflavins were the lowest contributors to the
total flavan-3-ol intake. The four theaflavin compounds
contributed almost equally to the total theaflavins in all three
regions.
Non-citrus fruit, particularly apples/pears, was the most
important food source of total flavan-3-ols in the MED
(56·2 %) and non-MED (34·1 %) regions (Table 3). Wine and
then tea were the other two major sources of flavan-3-ols in
these two regions. On the other hand, tea (51·3 %) was the
most prominent source of total flavan-3-ols in the UK,
followed by non-citrus fruit (19·9 %) and wine (6·1 %). The
major food sources of catechins and epicatechins in all
three regions were tea, non-citrus fruits and wine; however,
chocolate candy/bars were also noteworthy dietary contribu-
tors. Tea was the lone source of theaflavins and a major
source of (epi)gallocatechins in all three regions (77·7 % in
the MED, 90·5 % in the non-MED and 95·1 % in the UK
region). The principal dietary source of total PA in the MED
region was non-citrus fruit (62·3 %) followed by wine
(17·3 %) and chocolate candy/bars (4·6 %). Non-citrus fruits
were also the main source of PA in the non-MED and UK
regions, but their contributions were smaller (48·0 and
37·2 %, respectively). In the non-MED region, wine was the
second most important source (12·6 %), followed by choco-
late/candy (6·6 %) and tea (5·0 %). Whereas in the UK region,
the secondary sources of PA were tea (15·0 %), wine (10·0 %),
cakes/pies/pastries/puddings (7·6 %) and pulses (7·1 %).
Sex-stratified analysis of the related factors showed similar
results; therefore the data are presented for men and women
combined (Table 4). Total flavan-3-ol intake and also the
intake stratified by monomers, PA and theaflavins were shown
to significantly vary between the geographical regions. The
intake of flavan-3-ol monomers and theaflavins in the UK
region was almost 4-fold and over 16-fold that of the MED
region, respectively. Conversely, PA intake was significantly
higher in the MED region (217·2 mg/d) compared to the
non-MED (177·9 mg/d) and the UK (198·4 mg/d) regions.
After adjusting for BMI and energy, women had significantly
higher intakes of total flavan-3-ols and their subclasses. The
intake of total flavan-3-ols and their subclasses was signifi-
cantly different between the age groups, being the highest

















Table 1. Adjusted* daily mean intakes (mg/d) of total and subgroups of flavan-3-ols in men and women by European Prospective Investigation into Cancer and Nutrition centre ordered from
south to north
(Mean values with their standard errors)
Men Women
Total
flavan-3-ols Monomers† PA Theaflavins‡
Total
flavan-3-ols Monomers† PA Theaflavins‡
Country and centre n Mean SE Mean SE Mean SE Mean SE n Mean SE Mean SE Mean SE Mean SE
Greece 1314 160·5 7·6 26·6 3·0 134·6 6·9 0·3 0·3 1373 124·8 7·4 20·7 2·9 101·0 6·5 0·6 0·3
Spain
Granada 214 279·4 18·7 41·7 7·3 221·8 22·7 0·6 1·1 300 151·7 15·8 20·5 6·2 132·3 15·4 0·1 0·8
Murcia 243 279·9 17·5 43·3 6·9 235·8 18·9 0·3 0·9 304 184·2 15·7 24·6 6·2 159·3 18·1 0·2 0·9
Navarra 444 286·2 13·0 40·1 5·1 235·2 15·5 0·0 0·8 271 180·6 16·6 21·1 6·5 164·1 18·2 0·0 0·9
San Sebastian 490 422·9 12·4 49·1 4·9 357·3 15·5 0·0 0·8 244 267·8 17·5 30·6 6·9 237·9 18·9 0·5 0·9
Asturias 386 498·3 13·9 54·7 5·5 455·2 14·9 0·1 0·7 324 286·3 15·2 33·6 6·0 236·8 15·6 0·3 0·8
Italy
Ragusa 168 317·5 21·1 53·9 8·3 239·6 28·8 0·4 1·4 138 235·4 23·3 37·3 9·2 193·7 27·1 0·4 1·4
Naples 403 217·4 13·6 36·9 5·4 204·6 14·4 0·4 0·7
Florence 271 382·7 16·6 61·1 6·5 325·5 18·4 0·7 0·9 784 264·3 9·8 54·5 3·8 209·5 11·3 1·0 0·6
Turin 676 435·3 10·5 73·6 4·1 370·8 11·9 0·6 0·6 392 303·6 13·8 66·6 5·4 228·2 19·4 1·5 1·0
Varese 327 379·9 77·2 5·9 258·7 23·5 1·4 1·2 794 276·4 9·7 70·4 3·8 192·4 9·9 1·7 0·5
France
South coast 620 251·5 11·0 66·1 4·3 181·6 9·3 5·2 0·5
South 1425 290·7 7·2 82·6 2·8 201·5 6·3 8·0 0·3
North-East 2059 290·2 6·0 78·6 2·4 210·0 5·3 7·3 0·3
North-West 631 281·4 10·9 83·7 4·3 185·9 9·8 8·8 0·5
Germany
Heidelberg 1034 301·6 8·5 88·3 3·3 207·6 15·9 6·6 0·8 1087 321·9 8·4 107·5 3·3 175·9 21·7 4·1 1·1
Potsdam 1233 277·1 7·8 72·0 3·1 209·7 8·7 4·3 0·4 1061 261·5 8·4 59·9 3·3 187·8 12·2 2·9 0·6
The Netherlands
Bilthoven 1024 220·6 8·6 77·8 3·4 128·1 20·8 10·4 1·0 1086 233·8 8·4 85·9 3·3 118·2 20·5 11·4 1·0
Utrecht 1870 286·8 6·3 114·6 2·5 159·0 5·4 16·0 0·3
UK
General population 403 439·6 13·6 213·5 5·4 217·1 12·8 29·3 0·6 571 377·6 11·4 178·6 4·5 172·9 10·5 25·3 0·5
Health-conscious 113 453·6 25·7 156·1 10·1 277·6 25·9 27·4 1·3 196 368·9 19·5 148·8 7·7 201·4 19·2 21·1 1·0
Denmark
Copenhagen 1356 325·5 7·4 96·0 2·9 229·6 11·2 9·7 0·6 1484 319·4 7·1 102·1 2·8 205·4 10·2 11·0 0·5
Aarhus 567 312·7 11·5 85·7 4·5 295·7 23·7 5·6 1·2 510 347·7 12·1 92·5 4·8 218·5 22·8 8·9 1·1
Sweden
Malmo¨ 1421 242·3 7·4 103·9 2·9 143·7 7·4 3·1 0·4 1711 235·3 6·7 98·9 2·6 140·7 5·6 3·1 0·3
Umea˚ 1344 287·4 7·5 113·9 2·9 171·8 7·8 3·7 0·4 1574 271·3 6·9 108·9 2·7 160·7 6·6 3·7 0·3
Norway
South and East 1004 298·9 8·7 85·2 3·4 218·2 8·7 6·6 0·4
North and West 793 289·2 9·8 70·5 3·8 232·0 9·9 4·9 0·5
PA, proanthocyanidins.
* Adjusted for age and weighted by season and day of recall.
† Sum of catechin, epicatechin and epicatechin 3-gallate, epigallocatechin 3-gallate, gallocatechin and catechin-3-gallate.
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in the 55- to 64-year-olds. It also increased with the level of
education completed and the level of physical activity. On
the other hand, current smokers and obese participants (BMI
$30 kg/m2) had the lowest intakes of total flavan-3-ols and
their subclasses.
Discussion
To our knowledge, this is the only study thus far assessing the
intake of total and flavan-3-ol monomers, PA and flavan-3-ol-
derived compounds as well as their food sources and associ-
ated factors in all twenty-seven EPIC centres of ten European
countries using a common expanded flavonoid FCDB and
dietary assessment method (24-HDR). Our results show a
wide range of total flavan-3-ol intakes following a south-to-
north geographical gradient. When stratified by regions, total
flavan-3-ol intake in the UK was about 2-fold that of the
MED region. This relatively steep gradient in flavan-3-ol
intake was mainly due to higher intakes of theaflavins and epi-
gallocatechins in northern EPIC cohorts; indeed the main
source of these subclasses of flavan-3-ols was found to be
tea. On the other hand, PA intake was found to be statistically
higher in the MED region, although large differences were
also noted among centres within the same region. The main
source of PA in the MED region was non-citrus fruit, chiefly
apples and pears, followed by wine, similar to what was pre-
viously reported for the EPIC Spanish cohort(23). Furthermore,
the almost-nil intake of theaflavins in Greece, Spain and
southern Italy indicates minimal consumption of tea in these
countries. Even so, the major sources identified for the total
and individual flavanols, PA and theaflavins were quite similar
except in the UK where pulses also formed a considerable
food source of PA.
A well-established inverse geographical gradient of CVD
mortality exists(42), which may seem paradoxical with the
north-to-south gradient for flavan-3-ol intake and the
observed beneficial effects of these compounds and flavo-
noid-rich foods against CVD(13,15,16). Though far-fetched at
this point to imply that flavan-3-ols have a significant role in
CVD, a few factors could be considered to help elucidate
this. Despite their higher observed antioxidant activity
in vitro (43,44), galloylated flavan-3-ol monomers (mainly
found in fermented/black teas) have lower bioavailability
than non-galloylated monomers(3,44) (found more commonly
in non-citrus fruit, green tea and cocoa). However, it is more
likely that other risk factors of CVD may be more prevalent
in the northern countries, such as high intake of SFA(45), low
intake of MUFA(46), low intake of fruits and vegetables(47),
low wine consumption(48), sedentary lifestyle(49,50) and social
class influences(51).
The present study also demonstrated that statistical differ-
ences exist in flavan-3-ol intakes among groups with different
socio-demographic, anthropometric and lifestyle character-
istics. Consumption of total flavan-3-ols, monomers and PA
increased with age up to about 64 years of age and then it
fell slightly. Similar results were seen in Spanish-EPIC(23),
US(8,22) and Australian(52) studies in adults. The intakes were
significantly higher in former and never smokers. Since the
major sources were tea and fruits, respectively, this suggests
possible interaction between the consumption of these food
sources and smoking habits(53,54). Additionally, two case–con-
trol studies suggested that a flavonoid-rich diet may protect
against pancreatic and lung cancer in smokers only(55,56).
Total flavan-3-ol intakes have been shown to be significantly
associated with a slower increase of BMI in women in
The Netherlands Cohort Study after adjusting for confounders
Table 2. Percentage contribution* of individual and subclasses of flavan-3-ols to subclass and total intake in the
European Prospective Investigation into Cancer and Nutrition cohort by European region
Region
MED countries Non-MED countries UK
Class and compound Class (%) Total (%) Class (%) Total (%) Class (%) Total (%)
Flavan-3-ol monomers 100·0 18·6 100·0 32·9 100·0 44·9
(þ )-Catechin 30·0 5·6 17·6 5·8 12·4 5·6
(2 )-Epigallocatechin 9·4 1·7 13·8 4·5 17·5 7·9
(2 )-Epicatechin 30·1 5·6 17·8 5·8 12·6 5·7
(2 )-Epicatechin 3-gallate 7·4 1·4 11·9 3·9 13·6 6·1
(2 )-Epigallocatechin 3-gallate 17·0 3·2 26·8 8·8 21·2 9·5
(þ )-Gallocatechin 1·7 0·3 3·0 1·0 4·7 2·1
(þ )-Catechin 3-gallate 4·3 0·8 9·1 3·0 18·1 8·1
PA or condensed tannins 100·0 80·8 100·0 64·8 100·0 48·8
PA dimers 19·1 15·4 20·7 13·4 28·9 14·1
PA trimers 6·8 5·5 7·2 4·7 7·8 3·8
PA 4–6mers 22·5 18·2 20·6 13·4 19·0 9·2
PA 7–10mers 16·7 13·5 15·0 9·7 13·6 6·6
PA polymers (.10mers) 34·9 28·2 36·4 23·6 30·7 15·0
Theaflavins 100·0 0·6 100·0 2·4 100·0 6·4
Theaflavin 26·0 0·2 26·0 0·6 25·9 1·6
Theaflavin-3,30-digallate 29·1 0·2 29·2 0·7 29·2 1·9
Theaflavin-30-gallate 22·7 0·1 22·6 0·5 22·7 1·4
Theaflavin-3-gallate 22·2 0·1 22·2 0·5 22·3 1·4
MED, Mediterranean; Non-MED, non-Mediterranean; PA, proanthocyanidins.
* Values are percentages derived from models adjusted for sex, age and weighted by season and day of recall.

















Table 3. Major food sources of dietary flavan-3-ols, their monomers, proanthocyanidins (PA) and theaflavins in the Mediterranean (MED), non-Mediterranean (non-MED) and UK regions*
Total flavan-3-ols (%) Monomers (%) Catechins (%) Epicatechins (%) EGC (%)† PA (%) Theaflavins (%)‡















Coffee, tea, herbal teas 8·2 28·8 51·8 36·5 69·2 83·7 5·8 19·4 47·7 7·7 26·1 41·8 81·9 93·7 96·4 1·2 5·0 15·0 100·0 100·0 100·0
Coffee 0·0 0·2 0·1 0·2 0·5 0·3 0·0 0·0 0·0 0·4 1·4 1·3 0·3 0·4 0·2 0·0 0·0 0·0 0·0 0·0 0·0
Tea 7·9 28·0 51·3 34·7 66·8 82·6 5·6 19·1 47·5 7·3 24·7 40·4 77·7 90·5 95·1 1·2 5·0 15·0 100·0 100·0 100·0
Herbal tea 0·3 0·6 0·4 1·6 1·9 0·8 0·1 0·3 0·2 0·0 0·1 0·0 4·0 2·8 1·1 0·0 0·0 0·0 0·0 0·0 0·0
Wine 17·4 10·2 6·1 18·1 6·3 2·8 41·0 24·5 15·8 18·6 11·4 7·7 0·8 0·2 0·1 17·3 12·6 10·0 0·0 0·0 0·0
Beer, cider 3·4 3·1 3·2 2·1 3·6 1·3 5·9 16·5 3·9 0·9 2·5 0·6 0·2 0·6 1·0 3·7 3·0 5·5 0·0 0·0 0·0
Milk beverages 0·0 0·1 2·4 0·0 0·0 2·3 0·0 0·1 4·2 0·0 0·1 12·4 0·0 0·0 0·3 0·0 0·1 2·9 0·0 0·0 0·0
Fruit and vegetable juices 0·5 2·3 0·9 0·3 1·4 0·4 0·3 2·0 0·7 0·6 6·0 2·5 0·0 0·0 0·1 0·5 2·8 1·5 0·0 0·0 0·0
Carbonated/soft/isotonic
drinks, diluted syrups
0·0 2·2 0·2 0·0 0·2 0·0 0·0 0·7 0·1 0·0 0·3 0·1 0·0 0·1 0·0 0·0 3·3 0·3 0·0 0·0 0·0
Fruit 56·2 34·1 19·9 31·8 10·2 4·8 38·1 24·2 18·9 54·9 29·1 17·9 9·0 1·6 0·5 62·3 48·0 37·2 0·0 0·0 0·0
Apple and pear 33·0 21·8 11·5 17·2 5·7 2·1 11·1 6·0 2·0 38·2 22·6 13·5 5·4 1·0 0·3 36·8 31·0 22·0 0·0 0·0 0·0
Stone fruits 13·9 4·7 2·7 8·8 1·4 0·6 15·1 4·0 2·4 11·3 3·4 1·7 2·2 0·2 0·1 15·2 6·6 5·1 0·0 0·0 0·0
Grape 5·0 2·3 2·0 3·5 0·9 0·5 5·8 2·6 2·3 4·4 1·9 1·7 1·0 0·2 0·1 5·4 3·1 3·7 0·0 0·0 0·0
Berries 3·1 3·4 2·0 0·7 0·6 0·3 1·6 2·6 1·5 0·3 0·7 0·4 0·3 0·1 0·1 3·7 4·9 3·9 0·0 0·0 0·0
Banana 0·3 0·7 0·8 1·2 1·4 1·2 3·9 8·3 10·0 0·0 0·0 0·0 0·0 0·0 0·0 0·1 0·4 0·6 0·0 0·0 0·0
Citrus fruit 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0
Kiwi 0·2 0·1 0·1 0·1 0·0 0·0 0·0 0·0 0·0 0·2 0·1 0·1 0·0 0·0 0·0 0·3 0·2 0·1 0·0 0·0 0·0
Other fruits 0·7 1·1 0·8 0·3 0·2 0·1 0·6 0·6 0·7 0·5 0·4 0·4 0·1 0·0 0·0 0·7 1·7 1·7 0·0 0·0 0·0
Chocolate candy/bars,
paste, confetti
4·7 5·7 3·2 5·6 4·2 1·3 3·5 4·6 2·1 9·2 12·2 5·7 4·3 2·0 0·5 4·6 6·6 5·5 0·0 0·0 0·0
Cakes, sweet pies, pastries,
puddings
2·3 3·1 3·4 2·4 1·9 1·3 1·7 3·1 2·9 5·0 8·3 7·5 2·2 1·3 0·8 3·1 5·8 7·6 0·0 0·0 0·0
Pulses 1·8 0·5 3·5 0·2 0·0 0·1 0·5 0·2 0·7 0·1 0·0 0·1 0·0 0·0 0·0 2·2 0·7 7·1 0·0 0·0 0·0
Cereal and cereal products 0·1 0·6 1·1 0·1 0·1 0·2 0·1 0·4 0·7 0·1 0·3 0·5 0·0 0·0 0·0 2·1 3·8 3·5 0·0 0·0 0·0
Soups 0·0 2·8 0·0 0·0 0·3 0·0 0·0 1·1 0·0 0·0 0·4 0·0 0·0 0·0 0·0 0·0 4·3 0·0 0·0 0·0 0·0
Other foods and beverages 5·4 6·5 4·3 2·9 2·6 1·8 3·0 3·3 2·2 2·9 3·4 3·2 1·5 0·6 0·4 3·0 3·9 3·9 0·0 0·0 0·0
EGC, (epi)gallocatechins.
* Values are percentages derived from models adjusted for centre, age and sex, and weighted by season and day of recall.
† Sum of epigallocatechin, epicatechin 3-gallate, epigallocatechin 3-gallate, gallocatechin and catechin-3-gallate.

















British Journal of Nutrition
including dieting, and some healthy habits such as fruit and
vegetable intake(57). Our study showed that the intakes of
total and subclasses of flavan-3-ols were lower in obese sub-
jects and, in addition, higher in physically active subjects.
Further investigation explaining the association between all
these factors and their role in obesity is needed. In our
study, intakes of PA increased with higher level of education,
and were found to be considerably low in the group without
formal schooling. In line with our findings, consumption of
fruits, fruit juice, wine and tea has been previously associated
with higher socio-economic status(58). These factors should be
taken into consideration when looking at disease prevention,
planning of healthy diets within a specific population and may
also be instrumental when establishing ‘lifespan essential’ diet-
ary reference intakes for flavan-3-ols, PA and theaflavins in
different populations, and in subgroups with unfavourable
lifestyle factors(59).
Major differences in total flavan-3-ol intake can be observed
between our study and other descriptive studies (Table 5).
Our estimates of total flavan-3-ol intake were much higher
than those reported in other countries and the main reason
being that some individual compounds or subclasses of
flavan-3-ols were not included in the total estimation of
flavan-3-ols in those studies. Comparison of the subclasses
(monomers, PA and theaflavins) may therefore be preferable.
Even then, the intakes may vary because of other important
factors involved in the estimation, such as different method-
ologies used to assess dietary intake of cohorts (FFQ, 24-
HDR, diet history, etc); compositional data of the compounds
may come from different sources or from older versions of the
USDA database(23,60), or the median intake reported rather
than the mean. The latter is particularly the case in the
Greek EPIC study(61). Finally, cohort characteristics, especially
those that are associated with flavan-3-ol consumption (e.g.
age and sex) may vary considerably. All these are to be kept
in mind when making comparisons. Flavan-3-ol monomer
intake reported recently for the UK and Ireland by Beking &
Vieira(62) and based on food balance sheets was about one-
third that of our reported intake for the UK region. The mono-
mer intake reported in an elderly Dutch cohort(63) as closer
but still slightly lower than our estimates for the Dutch cohorts
of Bilthoven and Utrecht even though, in our study, intakes
were found to be higher in older age groups. Monomer
intakes reported recently in Italy(21) and for Spanish(23) and
Greek(61) EPIC cohorts were within our ranges for those
countries. As for other countries known to have a tea culture,
Table 4. Socio-demographic, lifestyle and anthropometric determinants of intake (mg/d) of total flavan-3-ols and their subgroups*
(Mean values with their standard errors)
Total flavan-3-ols Monomers† Proanthocyanidins Theaflavins‡
n Mean SE P§ Mean SE P§ Mean SE P§ Mean SE P§
Region ,0·001 ,0·001 ,0·001 ,0·001
Mediterranean countries 11 285 268·8 2·6 50·0 1·0 217·2 2·2 1·6 0·1
Non-Mediterranean countries 23 469 274·7 1·9 90·2 .7 177·9 1·5 6·5 0·1
UK 1283 406·6 7·6 182·4 3·0 198·4 6·3 25·9 0·3
Sex ,0·001 0·002 ,0·001 0·019
Male 13 028 280·7 3·0 73·6 1·2 201·6 2·5 5·5 0·1
Female 23 009 296·5 2·2 78·1 0·9 212·5 1·8 5·9 0·1
Age (years) ,0·001 0·004 ,0·001 0·340
35–44 3335 262·6 5·0 72·2 2·0 185·0 4·1 5·4 0·2
45–54 12 595 274·9 2·7 73·9 1·1 195·2 2·2 5·7 0·1
55–64 14 940 302·5 2·6 78·1 1·0 218·7 2·1 5·7 0·1
65–74 5167 298·3 4·3 76·7 1·7 215·7 3·6 5·9 0·2
Education level completed ,0·001 ,0·001 ,0·001 ,0·001
None 1709 267·4 7·7 69·6 3·0 192·5 6·4 5·4 0·3
Primary 10 469 258·0 3·0 59·4 1·2 194·1 2·5 4·4 0·1
Technical/professional 8038 281·1 3·5 72·0 1·4 204·0 2·9 5·1 0·1
Secondary school 7152 303·1 3·5 82·1 1·4 215·1 2·9 6·0 0·1
Post-secondary 8155 329·6 3·3 96·3 1·3 225·7 2·8 7·7 0·1
Smoking status ,0·001 ,0·001 ,0·001 ,0·001
Never 17 483 295·5 2·5 79·8 1·0 209·8 2·0 6·0 0·1
Former 10 288 301·4 2·9 80·2 1·2 215·0 2·4 6·2 0·1
Smoker 7726 256·1 3·3 62·4 1·3 189·3 2·7 4·5 0·1
Physical activity ,0·001 ,0·001 ,0·001 0·002
Inactive 7463 274·5 3·2 71·9 1·3 197·3 2·6 5·3 0·1
Moderately inactive 11 969 283·8 2·6 75·0 1·1 203·1 2·1 5·7 0·1
Moderately active 8400 299·1 3·1 79·0 1·3 214·1 2·5 6·1 0·1
Active 6380 304·5 3·5 79·1 1·5 219·6 2·8 5·8 0·2
BMI (kg/m2) ,0·001 ,0·001 0·012 ,0·001
, 25 16 854 297·1 2·6 81·6 1·0 209·3 2·1 6·3 0·1
25 to ,30 13 766 285·2 2·6 72·5 1·0 207·3 2·1 5·4 0·1
. 30 5417 270·0 3·9 66·8 1·6 198·4 3·2 4·7 0·2
* General linear model adjusted for age, sex, region, BMI (whenever not stratified for the respective variables) and energy intake, and weighted by season and day of recall.
† Sum of catechins, epicatechins and (epi)gallocatechins.
‡ Sum of theaflavin, theaflavin-30-gallate, theaflavin-3 gallate and theaflavin-3,30-digallate.
§P values are for overall differences in mean consumption by general linear model among the socio-demographic, lifestyle and anthropometric subgroups.











































Finland(66) 128 C, EC, PA 12 ns ns – 116 – National Finnish
database
2007/25–64/both 48DR
Ireland(62) 47 C, EC, EGC 47 ns ns ns – – USDA 2007 and
various other
ns/ns/ns Food balance sheets
UK(62) 52 C, EC, EGC 52 ns ns ns – – USDA 2007 and
various other
ns/ns/ns Food balance sheets
UK(64)† 154 C, EC, EGC, PA 119 7 25 88 34 – Various 404/32–88/both FFQ
Denmark(52) 148 C, EC, EGC, theaflavins,
thearubigins
ns ns ns ns – ns USDA 2003 ns/ns/both Dietary history
The Netherlands(52) 145 C, EC, EGC, theaflavins,
thearubigins
ns ns ns ns – ns USDA 2003 6200/1–92/both 2 d dietary record
The Netherlands(63) 72 C, EC, EGC 72 ns ns ns – – Own data 1266/65–84/men 1-month dietary history
France(65) 338 C, EC, EGC, PA 87 ns ns ns 227 9 Phenol-Explorer 13 017/35–60/both 24DR
Italy(21) 343 C, EC, EGC, PA,
theaflavins, thearubigins
53 ns ns ns 290 ns USDA 2003, 2004 547/22–80/both FFQ
Spain EPIC(23) 221 C, EC, EGC, theaflavins,
thearubigins
30 13 11 6 189 0 USDA 2004, 2007 40 683/35–64/both FFQ
Greece EPIC(61)‡ 89 C, EC, ECG, PA 13 6 6 1 75 – USDA 2004, 2007 28 572/30–76/both FFQ
USA(22,67) 251 (C, EC, theaflavins,
thearubigins), PA
ns ns ns ns 95 ns USDA 2004, 2007 8809/19 þ /both 24DR
Australia(52) 422 C, EC, EGC, theaflavins,
thearubigins
188 9 17 162 – 22 USDA 2003 17 326/19 þ /both 24DR
Japan(60) 380 C, EC, EGC 380 ns ns ns – – National Japanese
database
514/40 þ /women 24 h dietary record
C, catechins; EC, epicatechins; EGC, (epi)gallocatechins; PA, proanthocyanidins; ns, not specified; –, value not provided by the original study; DR, dietary recall; USDA, US Department of Agriculture.
* Where applicable and when not provided by the study, total flavan-3-ols were calculated as the sum of the subgroups.
† Median values given instead of the mean.
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Otaki et al.(60) have estimated monomer intake in Japanese
women to be around 380 mg/d, more than double the value
we reported for the UK region. This is probably because of
higher consumption of non-fermented tea, such as green
tea, in Japan. Green tea is a rich source of flavan-3-ol mono-
mers but not a source of theaflavins, which was found exclu-
sively in black tea, the tea more commonly consumed in
the UK. In contrast, monomer intake (188 mg/d) reported in
Australia was comparable to our value in the UK region. PA
intake for Spain in our study is slightly higher than previously
reported for the EPIC Spain cohort; however, the previous
study used dietary history questionnaires and only the USDA
food composition values in their estimation of flavan-3-ols(23).
A recent Italian case–control study assessed the mean PA
intake to be around 290 mg/d which is within the range
of the Italian values in our study(21). However, most PA
estimations have been done in case–control studies, which
assess small groups of controls and not always all the sub-
groups of PA were included(20,21,64). Surprisingly, Greece
being a MED country had the lowest intake of PA of all
EPIC centres. Among the other previously mentioned factors
for this difference, this finding is also supported by the
lower consumption of fruit in Greece compared to Italy and
Spain reported previously in EPIC studies(47). Perez-Jimenez
et al.(65) reported intakes of flavan-3-ol monomers (114 mg/d),
PA (191 mg/d) and theaflavins (16 mg/d) in French women
that are within the range of our values for the French EPIC
centres. A limited number of descriptive studies is available
on PA to facilitate a comparison with non-EPIC countries.
Using their own composition database, Ovaskainen et al.(66)
reported lower PA intakes for a Finnish population compared
to the northern EPIC countries such as Sweden and Norway.
The sources of PA in northern EPIC countries were found to
be similar to those in Finland, with the exception of berries,
which were not singled out in our study but were an import-
ant source of PA in Finland. These differences in intake and
food sources compared to our study are most probably due
to the varying study variables already exposed earlier. Finally,
Wang et al.(67) recently estimated PA intake for the US popu-
lation to be about 95 mg/d. This is still slightly lower than
the lowest intakes found in our study (Greek cohorts). Clearly,
more consistent methods of intake estimation between and
within countries are needed. Parallel to that, improved
methods for identification and quantification of some flavan-
3-ol compounds, such as thearubigins, are needed to allow
for more exhaustive flavonoid composition databases.
The use of a common expanded flavonoid database
provided us with greater coverage of foods representative of
the EPIC countries while allowing for comparisons of results
across the countries. Despite the fact that we applied retention
factors to foods prepared by cooking, we estimated higher
intakes than in the previous studies. Moreover, our values
are likely to be underreported due to spices and herbs often
not accounted for during diet assessment and because a
small proportion (2–16 %) of flavan-3-ol analytical values in
our study was still missing. The underestimation of intakes
is also probably due to the omission of dietetic supplements
in this analysis. However, few consumers of herb/plant
supplements participated in this study (the highest was 5 %
reported in Denmark)(68).
To our knowledge, this is the largest study to date describ-
ing flavan-3-ol and PA intake across several European
countries. Since not all the EPIC cohorts are representative
of the population, the observed level of intake cannot be
extrapolated to the general population of each region.
In summary, this study provides total and individual flavan-
3-ol, PA and theaflavin intakes for ten EPIC countries by sex
and EPIC centre. The major dietary contributors of these
flavonoid subclasses are described by the MED, non-MED
and UK regions. In addition, we show that socio-demo-
graphic, anthropometric and lifestyle factors associated with
differential consumption of flavan-3-ols, PA and theaflavins
exist. Combined with more elucidated information on the
bioavailability of these compounds, these descriptive data
will be valuable in future evaluations of total and individual
flavan-3-ols and their role in health and disease in the
European population.
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Annex 1. Adjusted* mean daily intakes (mg/d) of flavan-3-ol monomer compounds by European Prospective Investigation into Cancer and Nutrition
centre ordered from south to north
















Country and centre n Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
Greece 2687 8·21 0·27 9·63 0·31 1·26 0·37 1·40 0·31 1·58 0·92 0·50 0·08 1·07 0·28
Spain
Granada 514 13·25 0·63 11·97 0·71 1·89 0·85 1·88 0·72 1·37 2·13 0·26 0·18 0·46 0·64
Murcia 547 15·67 0·61 12·59 0·68 1·92 0·82 1·86 0·69 1·18 2·05 0·33 0·17 0·40 0·61
Navarra 715 14·46 0·54 12·50 0·61 1·67 0·73 0·79 0·62 0·88 1·83 0·16 0·15 0·15 0·55
San Sebastian 734 17·69 0·55 16·60 0·62 2·35 0·75 1·26 0·63 1·41 1·87 0·24 0·16 0·33 0·56
Asturias 710 17·85 0·53 19·25 0·59 2·64 0·72 1·48 0·60 2·35 1·79 0·21 0·15 0·33 0·54
Italy
Ragusa 306 15·04 0·81 14·74 0·91 4·28 1·09 2·47 0·92 8·09 2·73 0·44 0·23 0·55 0·82
Naples 403 10·34 0·70 11·46 0·79 3·64 0·95 2·45 0·80 8·05 2·37 0·40 0·20 0·56 0·71
Florence 1055 16·43 0·50 17·22 0·56 5·81 0·67 3·92 0·56 12·54 1·67 0·79 0·14 1·09 0·50
Turin 1068 21·84 0·45 20·31 0·50 6·44 0·60 4·61 0·51 14·57 1·51 0·93 0·13 1·38 0·45
Varese 1121 18·87 0·46 18·36 0·52 7·67 0·62 6·10 0·53 19·86 1·56 1·13 0·13 1·80 0·47
France
South coast 620 14·53 0·56 17·26 0·63 7·63 0·76 7·19 0·64 10·71 1·91 1·84 0·16 6·96 0·57
South 1425 15·41 0·37 18·37 0·42 11·01 0·50 9·79 0·42 14·63 1·26 2·76 0·11 10·62 0·38
North-East 2059 15·80 0·31 18·44 0·35 10·07 0·42 8·86 0·35 13·62 1·05 2·45 0·09 9·32 0·31
North-West 631 14·83 0·56 17·54 0·63 11·68 0·76 9·85 0·64 15·31 1·89 2·99 0·16 11·49 0·57
Germany
Heidelberg 2121 18·94 0·31 20·42 0·35 13·12 0·42 13·03 0·35 22·91 1·04 2·43 0·09 7·04 0·31
Potsdam 2294 16·16 0·29 15·73 0·33 7·27 0·40 8·76 0·34 11·45 1·00 1·63 0·08 4·98 0·30
The Netherlands
Bilthoven 2110 14·77 0·31 13·98 0·35 12·32 0·42 9·77 0·36 15·22 1·06 3·36 0·09 12·45 0·32
Utrecht 1870 14·46 0·33 16·50 0·37 19·40 0·44 15·25 0·37 23·61 1·10 5·18 0·09 20·24 0·33
UK
General population 974 22·76 0·46 23·91 0·51 35·07 0·62 26·44 0·52 42·61 1·55 9·30 0·13 35·96 0·46
Health-conscious 309 19·87 0·83 20·06 0·93 26·18 1·12 21·93 0·94 31·08 2·81 6·82 0·24 26·53 0·84
Denmark
Copenhagen 2840 23·27 0·26 19·09 0·30 12·92 0·36 10·65 0·30 16·46 0·89 3·69 0·08 12·93 0·27
Aarhus 1077 21·85 0·43 20·99 0·48 10·50 0·58 8·98 0·49 13·87 1·45 2·92 0·12 10·01 0·44
Sweden
Malmo¨ 3132 12·27 0·26 13·83 0·29 14·30 0·35 12·01 0·30 43·44 0·88 2·10 0·07 3·42 0·27
Umea˚ 2918 11·15 0·26 14·09 0·29 16·33 0·35 13·63 0·30 49·99 0·88 2·35 0·07 3·89 0·27
Norway
South and East 1004 13·39 0·45 15·81 0·50 12·17 0·61 10·70 0·51 22·04 1·52 2·57 0·13 8·48 0·45
North and West 793 11·70 0·50 14·68 0·57 9·46 0·68 8·93 0·57 17·75 1·70 1·88 0·14 6·09 0·51
* Adjusted for sex and age, and weighted by season and day of recall.

















Annex 2. Adjusted* mean daily intakes (mg/d) of proanthocyanidin (PA) and theaflavin subgroups by European Prospective Investigation into Cancer and Nutrition centre ordered from south to north


















Country and centre n Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
Greece 2687 17·9 0·8 7·7 0·3 24·8 0·9 19·0 0·7 48·9 2·3 0·13 0·06 0·12 0·05 0·12 0·05 0·11 0·05
Spain
Granada 514 36·4 1·8 12·7 0·7 41·9 2·1 30·0 1·6 63·1 5·4 0·07 0·13 0·06 0·11 0·06 0·11 0·06 0·11
Murcia 547 38·7 1·7 14·2 0·7 46·9 2·0 33·2 1·5 64·8 5·2 0·06 0·13 0·05 0·11 0·05 0·11 0·05 0·11
Navarra 715 39·1 1·5 13·1 0·6 45·9 1·8 34·1 1·4 70·4 4·6 0·01 0·11 0·01 0·10 0·01 0·10 0·01 0·10
San Sebastian 734 56·1 1·6 20·3 0·6 69·8 1·8 53·3 1·4 105·7 4·7 0·06 0·11 0·05 0·10 0·05 0·10 0·05 0·10
Asturias 710 61·7 1·5 25·7 0·6 83·0 1·8 63·0 1·3 114·6 4·5 0·05 0·11 0·04 0·10 0·04 0·10 0·04 0·09
Italy
Ragusa 306 44·3 2·3 15·5 0·9 52·6 2·7 38·3 2·1 79·6 6·9 0·13 0·17 0·11 0·15 0·11 0·15 0·11 0·14
Naples 403 31·1 2·0 13·3 0·8 43·5 2·3 30·6 1·8 61·5 6·0 0·14 0·15 0·12 0·13 0·12 0·13 0·11 0·13
Florence 1055 50·1 1·4 18·5 0·6 60·9 1·6 44·7 1·3 90·6 4·2 0·22 0·10 0·19 0·09 0·19 0·09 0·19 0·09
Turin 1068 61·7 1·3 19·9 0·5 67·3 1·5 49·5 1·1 100·1 3·8 0·26 0·09 0·22 0·08 0·22 0·08 0·21 0·08
Varese 1121 53·4 1·3 17·0 0·5 56·0 1·5 41·4 1·2 85·1 3·9 0·37 0·10 0·32 0·08 0·32 0·08 0·31 0·08
France
South coast 620 36·7 1·6 12·2 0·6 40·1 1·9 28·0 1·4 62·8 4·8 1·40 0·12 1·23 0·10 1·23 0·10 1·20 0·10
South 1425 40·8 1·1 13·9 0·4 44·1 1·2 31·3 0·9 69·6 3·2 2·14 0·08 1·88 0·07 1·88 0·07 1·84 0·07
North-East 2059 41·9 0·9 14·8 0·4 46·2 1·0 32·0 0·8 69·5 2·6 1·88 0·06 1·64 0·06 1·64 0·06 1·61 0·06
North-West 631 40·5 1·6 13·6 0·6 42·8 1·9 30·8 1·4 61·0 4·8 2·31 0·12 2·03 0·10 2·03 0·10 1·99 0·10
Germany
Heidelberg 2121 45·5 0·9 17·2 0·4 43·9 1·0 32·4 0·8 69·4 2·6 1·39 0·06 1·20 0·06 1·20 0·06 1·19 0·06
Potsdam 2294 33·1 0·8 14·9 0·3 44·4 1·0 32·8 0·8 74·5 2·5 0·92 0·06 0·80 0·05 0·80 0·05 0·79 0·05
The Netherlands
Bilthoven 2110 29·6 0·9 10·6 0·4 29·9 1·0 21·0 0·8 44·4 2·7 2·52 0·07 2·20 0·06 2·20 0·06 2·16 0·06
Utrecht 1870 36·1 0·9 12·1 0·4 33·7 1·1 24·3 0·8 50·1 2·8 4·10 0·07 3·59 0·06 3·59 0·06 3·52 0·06
UK
General population 974 58·5 1·3 14·8 0·5 34·3 1·5 23·9 1·2 52·7 3·9 7·32 0·10 6·41 0·08 6·41 0·08 6·29 0·08
Health-conscious 309 51·9 2·3 18·0 1·0 46·8 2·8 36·1 2·1 85·2 7·1 5·37 0·17 4·70 0·15 4·70 0·15 4·62 0·15
Denmark
Copenhagen 2840 58·9 0·7 15·1 0·3 43·5 0·9 30·4 0·7 65·5 2·3 2·62 0·05 2·30 0·05 2·30 0·05 2·25 0·05
Aarhus 1077 57·9 1·2 17·7 0·5 51·7 1·4 36·6 1·1 69·3 3·7 2·02 0·09 1·77 0·08 1·77 0·08 1·74 0·08
Sweden
Malmo¨ 3132 26·3 0·7 10·1 0·3 28·2 0·9 19·4 0·7 50·3 2·2 0·83 0·05 0·72 0·05 0·72 0·05 0·69 0·05
Umea˚ 2918 23·4 0·7 10·3 0·3 28·2 0·9 21·8 0·7 80·7 2·2 0·95 0·05 0·82 0·05 0·82 0·05 0·79 0·05
Norway
South and East 1004 32·2 1·3 12·0 0·5 35·6 1·5 28·5 1·1 98·8 3·8 1·73 0·09 1·50 0·08 1·50 0·08 1·48 0·08
North and West 793 31·1 1·4 12·6 0·6 37·1 1·7 29·5 1·3 103·7 4·3 1·23 0·10 1·07 0·09 1·07 0·09 1·06 0·09
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